© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 17, 1501-1504,
September 1, 1999
© 1999 Oxford University Press
BRIEF COMMUNICATION |
Enhancement of Tumor Response to 
-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme
Affiliations of authors: L. Milas, K. Kishi, N. Hunter, K. Mason, P. J. Tofilon, Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston; J. L. Masferrer, Pharma Research and Development, Searle, Monsanto, St. Louis, MO.
Correspondence to: Luka Milas, M.D., Ph.D., Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 066, Houston, TX 77030-4095 (e-mail: lmilas@mdanderson.org).
Prostaglandins are arachidonate metabolites produced in virtually all mammalian tissues and possess diverse biologic capabilities, including vasoconstriction, vasodilatation, stimulation or inhibition of platelet aggregation, and immunomodulation, primarily immunosupression (1-4). They are implicated in the promotion of development and growth of malignant tumors (4-7). They are also involved in the response of tumor and normal tissues to cytotoxic agents such as ionizing radiation (8). Prostaglandin production is mediated by two cyclooxygenase enzymes: cyclooxygenase-1 and cyclooxygenase-2. Cyclooxygenase-1 is constitutively expressed and is ubiquitous, and cyclooxygenase-2 is induced by diverse inflammatory stimuli (7,9).
Nonsteroidal anti-inflammatory drugs (NSAIDs) or agents inhibit cyclooxygenase enzymes
and consequently can prevent, inhibit, or abolish the effects of prostaglandins. Increasing
evidence shows that NSAIDs can inhibit the development of cancer in both experimental animals
and in humans (7), can reduce the size of
REFERENCES
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. E. Milenic, K. Garmestani, E. D. Brady, K. E. Baidoo, P. S. Albert, K. J. Wong, J. Flynn, and M. W. Brechbiel Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease Clin. Cancer Res., August 15, 2008; 14(16): 5108 - 5115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsubochi, N. Sato, M. Hiyama, M. Kaimori, S. Endo, Y. Sohara, and T. Imai Combined Analysis of Cyclooxygenase-2 Expression With p53 and Ki-67 in Nonsmall Cell Lung Cancer. Ann. Thorac. Surg., October 1, 2006; 82(4): 1198 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lee, J. Frischer, A. Serur, J. Huang, J.-O Bae, Z. N. Kornfield, L. Eljuga, C. J. Shawber, N. Feirt, M. Mansukhani, et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res., April 15, 2006; 66(8): 4378 - 4384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Xi, S. E. Baldus, U. Warnecke-Eberz, J. Brabender, S. Neiss, R. Metzger, F. C. Ling, H. P. Dienes, E. Bollschweiler, S. Moenig, et al. High Cyclooxygenase-2 Expression Following Neoadjuvant Radiochemotherapy Is Associated with Minor Histopathologic Response and Poor Prognosis in Esophageal Cancer Clin. Cancer Res., December 1, 2005; 11(23): 8341 - 8347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Shin, J. S. Park, H. S. Kim, H. J. Jun, G. E. Kim, C. O. Suh, Y. S. Yun, and H. Pyo Radiosensitivity Enhancement by Celecoxib, a Cyclooxygenase (COX)-2 Selective Inhibitor, via COX-2-Dependent Cell Cycle Regulation on Human Cancer Cells Expressing Differential COX-2 Levels Cancer Res., October 15, 2005; 65(20): 9501 - 9509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mazhar, R. Gillmore, and J. Waxman COX and cancer QJM, October 1, 2005; 98(10): 711 - 718. [Full Text] [PDF]
|
|
|
|
|
|
S. T. Palayoor, M. J. Arayankalayil, A. Shoaibi, and C. N. Coleman Radiation Sensitivity of Human Carcinoma Cells Transfected with Small Interfering RNA Targeted against Cyclooxygenase-2 Clin. Cancer Res., October 1, 2005; 11(19): 6980 - 6986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Kim, V. Bossuyt, T. Ponn, D. Lannin, and B. G. Haffty Cyclooxygenase-2 Expression in Postmastectomy Chest Wall Relapse Clin. Cancer Res., July 15, 2005; 11(14): 5199 - 5205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K-B Tan and T C Putti Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications J. Clin. Pathol., May 1, 2005; 58(5): 535 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Liao, R. Komaki, L. Milas, C. Yuan, M. Kies, J. Y. Chang, M. Jeter, T. Guerrero, G. Blumenschien, C. M. Smith, et al. A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3342 - 3348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Uchida, S. Schneider, J. M. Yochim, H. Kuramochi, K. Hayashi, K. Takasaki, D. Yang, K. D. Danenberg, and P. V. Danenberg Intratumoral COX-2 Gene Expression Is a Predictive Factor for Colorectal Cancer Response to Fluoropyrimidine-Based Chemotherapy Clin. Cancer Res., May 1, 2005; 11(9): 3363 - 3368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jeremic, B. Milicic, A. Dagovic, Z. Vaskovic, and L. Tadic Radiation Therapy With or Without Concurrent Low-Dose Daily Chemotherapy in Locally Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., September 1, 2004; 22(17): 3540 - 3548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Biarc, I. S. Nguyen, A. Pini, F. Gosse, S. Richert, D. Thierse, A. Van Dorsselaer, E. Leize-Wagner, F. Raul, J.-P. Klein, et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis) Carcinogenesis, August 1, 2004; 25(8): 1477 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown and R. N. DuBois Cyclooxygenase-2 in Lung Carcinogenesis and Chemoprevention: Roger S. Mitchell Lecture Chest, May 1, 2004; 125(5_suppl): 134S - 140S. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lanza-Jacoby, A. P. Dicker, S. Miller, F. E. Rosato, J. T. Flynn, S. N. Lavorgna, and R. Burd Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice Mol. Cancer Ther., April 1, 2004; 3(4): 417 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Kim, Y. B. Kim, N. H. Cho, H.-C. Chung, H. R. Pyo, J. D. Lee, T. K. Park, W. S. Koom, M. Chun, and C. O. Suh Synchronous Coexpression of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in Carcinomas of the Uterine Cervix: A Potential Predictor of Poor Survival Clin. Cancer Res., February 15, 2004; 10(4): 1366 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Davis, J. M. O'Neal, M. D. Pagel, B. S. Zweifel, P. P. Mehta, D. M. Heuvelman, and J. L. Masferrer Synergy between Celecoxib and Radiotherapy Results from Inhibition of Cyclooxygenase-2-Derived Prostaglandin E2, a Survival Factor for Tumor and Associated Vasculature Cancer Res., January 1, 2004; 64(1): 279 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Nathoo, G H Barnett, and M Golubic The eicosanoid cascade: possible role in gliomas and meningiomas J. Clin. Pathol., January 1, 2004; 57(1): 6 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Tessner, F. Muhale, S. Schloemann, S. M. Cohn, A. R. Morrison, and W. F. Stenson Ionizing radiation up-regulates cyclooxygenase-2 in I407 cells through p38 mitogen-activated protein kinase Carcinogenesis, January 1, 2004; 25(1): 37 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Makowski, T. Grzela, J. Niderla, M. Lazarczyk, P. Mroz, M. Kopee, M. Legat, K. Strusinska, K. Koziak, D. Nowis, et al. Inhibition of Cyclooxygenase-2 Indirectly Potentiates Antitumor Effects of Photodynamic Therapy in Mice Clin. Cancer Res., November 1, 2003; 9(14): 5417 - 5422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Choy and L. Milas Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance? J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Palayoor, P. J. Tofilon, and C. N. Coleman Ibuprofen-mediated Reduction of Hypoxia-inducible Factors HIF-1{alpha} and HIF-2{alpha} in Prostate Cancer Cells Clin. Cancer Res., August 1, 2003; 9(8): 3150 - 3157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.K. Altorki, R.S. Keresztes, J.L. Port, D.M. Libby, R.J. Korst, D.B. Flieder, C.A. Ferrara, D.F. Yankelevitz, K. Subbaramaiah, M.W. Pasmantier, et al. Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., July 15, 2003; 21(14): 2645 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37. [Abstract] [PDF]
|
|
|
|
|
|
M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Portnow, S. Suleman, S. A. Grossman, S. Eller, and K. Carson A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas Neuro-oncol, January 1, 2002; 4(1): 22 - 25. [Abstract] [PDF]
|
|
|
|
|
|
H. Pyo, H. Choy, G. P. Amorino, J.-s. Kim, Q. Cao, S. K. Hercules, and R. N. DuBois A Selective Cyclooxygenase-2 Inhibitor, NS-398, Enhances the Effect of Radiation in Vitro and in Vivo Preferentially on the Cells That Express Cyclooxygenase-2 Clin. Cancer Res., October 1, 2001; 7(10): 2998 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Blumenthal, C. Waskewich, D. M. Goldenberg, W. Lew, C. Flefleh, and J. Burton Chronotherapy and Chronotoxicity of the Cyclooxygenase-2 Inhibitor, Celecoxib, in Athymic Mice Bearing Human Breast Cancer Xenografts Clin. Cancer Res., October 1, 2001; 7(10): 3178 - 3185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Petersen, S. Petersen, L. Milas, F. F. Lang, and P. J. Tofilon Enhancement of Intrinsic Tumor Cell Radiosensitivity Induced by a Selective Cyclooxygenase-2 Inhibitor Clin. Cancer Res., June 1, 2000; 6(6): 2513 - 2520. [Abstract] [Full Text]
|
|
|
|
|
|
T. Hida, K.-i. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, T. Mitsudomi, T. Sugiura, M. Ogawa, and T. Takahashi Cyclooxygenase-2 Inhibitor Induces Apoptosis and Enhances Cytotoxicity of Various Anticancer Agents in Non-Small Cell Lung Cancer Cell Lines Clin. Cancer Res., May 1, 2000; 6(5): 2006 - 2011. [Abstract] [Full Text]
|
|
|
|
|
|
, , , , , J. , P. , and Preferential Enhancement of Tumor Radioresponse by a Cyclooxygenase-2 Cancer Res., March 1, 2000; 60(5): 1326 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gallo Re: Enhancement of Tumor Response to {gamma}-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme J Natl Cancer Inst, February 16, 2000; 92(4): 346 - 346. [Full Text] [PDF]
|
|
|
|
|
|
L. Milas, K. A. Mason, and P. J. Tofilon RESPONSE: Re: Enhancement of Tumor Response to {gamma}-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme J Natl Cancer Inst, February 16, 2000; 92(4): 346a - 347a. [Full Text] [PDF]
|
|